Hepatitis

Supply Updates Announced for Recombivax HBV Vaccines

Supply Updates Announced for Recombivax HBV Vaccines

By

The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.

FDA: Chocolates, Candies May Be Contaminated With Hepatitis A

FDA: Chocolates, Candies May Be Contaminated With Hepatitis A

Worker at Bauer's Candies facility in Kentucky tested positive for hepatitis A.

HIV & Cancer Risk: Expert Interview

HIV & Cancer Risk: Expert Interview

By

Although rates of AIDS-defining malignancies have declined in recent decades, cancer remains a leading cause of mortality in people living with HIV.

USPSTF Affirms Guidance for Hep B Screening at First Prenatal Visit

USPSTF Affirms Guidance for Hep B Screening at First Prenatal Visit

The USPSTF recommends hepatitis B virus (HBV) infection screening in pregnant women at their first prenatal visit.

Population Based Screening Crucial for Early Diagnosis/Treatment of STIs

Population Based Screening Crucial for Early Diagnosis/Treatment of STIs

By

Adopting suitable protocols for the early diagnosis of STIs is necessary to allow implementation of prevention measures that will safeguard public health.

Temporary Decline in CD4 T-Cell Count After Hepatitis C Infection in PLWHIV

Temporary Decline in CD4 T-Cell Count After Hepatitis C Infection in PLWHIV

By

When hepatitis C is acquired in patients with HIV infection, CD4 T-cell counts temporarily decline after HCV seroconversion.

Tenofovir Disoproxil Fumarate Approved for Use in Younger Patients With HBV

Tenofovir Disoproxil Fumarate Approved for Use in Younger Patients With HBV

By

The Indication section has been revised to state that Viread is intended for use in the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg.

Survival Similar With Donor Hearts From Donors With Hepatitis C

Survival Similar With Donor Hearts From Donors With Hepatitis C

Transplant patients with hearts from donors with HCV infection and obese donors have similar survival rates as patients with other donor hearts.

Updated Recommendations, Hepatitis A Vaccine Postexposure Prophylaxis and Travel

Updated Recommendations, Hepatitis A Vaccine Postexposure Prophylaxis and Travel

By

The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.

Targeted Hep C Testing Misses High Number of Cases in Prisons

Targeted Hep C Testing Misses High Number of Cases in Prisons

Findings based on birth cohort, risk-based testing versus opt-out testing in prison system.

Real-World Data Show Rising HCV Epidemic Among Young Adults

Real-World Data Show Rising HCV Epidemic Among Young Adults

By

The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.

HCV Reinfection Rates Examined Following Successful Treatment

HCV Reinfection Rates Examined Following Successful Treatment

By

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

HCV Treatment Linked to Reduced Risk of Incident CVD Events

HCV Treatment Linked to Reduced Risk of Incident CVD Events

By

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

By

In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

By

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

By

The study aimed to determine whether direct-acting antiviral therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up.

2017 Hepatitis A Outbreaks Tied to Drug Use, Homelessness

2017 Hepatitis A Outbreaks Tied to Drug Use, Homelessness

Investigations of hepatitis A outbreaks in four states in 2017 suggested a shift toward increasing person-to-person transmission of hepatitis A.

HBV Treatment Evaluation, Initiation Rates Compared Among Various Practice Settings

HBV Treatment Evaluation, Initiation Rates Compared Among Various Practice Settings

By

The aim of the study was to assess both treatment evaluation and treatment initiation rates from various practice settings between January 2002 and December 2016.

Over Two Million People Living With Hep C From 2013 to 2016

Over Two Million People Living With Hep C From 2013 to 2016

During 2013 to 2016, more than two million people in the United States had current hepatitis C virus infection.

CDC Updates Recommendations for Hepatitis A Vaccination for International Travel

CDC Updates Recommendations for Hepatitis A Vaccination for International Travel

By

The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group updated recommendations for the use of hepatitis A vaccine for PEP and PrEP.

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

By

The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

By

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong

First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong

Hepatitis E infection identified in 56-year-old man who had received a liver transplant in May 2017.

Authorized Generics of Epclusa, Harvoni Will Soon Be Available for HCV Treatment

Authorized Generics of Epclusa, Harvoni Will Soon Be Available for HCV Treatment

By

The list price for the generics is $24,000 for the most common course of therapy.

Recipients of Popular Facial May Have Been Exposed to HIV, Hepatitis

Recipients of Popular Facial May Have Been Exposed to HIV, Hepatitis

Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC.

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

By

The FDA has approved Mulpleta for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hepatitis B core Antibody (anti-HB c+) organs may be a safe and ethical transplant option in an era where increased medical knowledge has enabled greater treatment for hepatitis.

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

Meeting World Health Organization targets for chronic hepatitis B by 2030 will be cost-effective.

Sign Up for Free e-newsletters